These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Novel agents in development for peripheral T-cell lymphoma. O'Connor OA Semin Hematol; 2010 Apr; 47 Suppl 1():S11-4. PubMed ID: 20359580 [TBL] [Abstract][Full Text] [Related]
11. Development of proteasome inhibitors in oncology and autoimmune diseases. Bennett MK; Kirk CJ Curr Opin Drug Discov Devel; 2008 Sep; 11(5):616-25. PubMed ID: 18729013 [TBL] [Abstract][Full Text] [Related]
12. Molecular biology and targeted therapy of cutaneous T-cell lymphomas. Klemke CD; Goerdt S G Ital Dermatol Venereol; 2008 Dec; 143(6):365-74. PubMed ID: 19169209 [TBL] [Abstract][Full Text] [Related]
14. Pralatrexate: an emerging new agent with activity in T-cell lymphomas. O'Connor OA Curr Opin Oncol; 2006 Nov; 18(6):591-7. PubMed ID: 16988580 [TBL] [Abstract][Full Text] [Related]
15. From a Better Understanding of the Mechanisms of Action of Histone Deacetylases Inhibitors to the Progress of the Treatment of Malignant Lymphomas and Plasma Cell Myeloma. Mihaila RG Recent Pat Anticancer Drug Discov; 2017 Nov; 12(4):283-295. PubMed ID: 28933264 [TBL] [Abstract][Full Text] [Related]
16. HDAC inhibitors in cancer care. Tofilon PJ; Camphausen K Oncology (Williston Park); 2010 Feb; 24(2):180-5. PubMed ID: 20361469 [TBL] [Abstract][Full Text] [Related]
17. HDAC inhibitors for the treatment of cutaneous T-cell lymphomas. Rangwala S; Zhang C; Duvic M Future Med Chem; 2012 Mar; 4(4):471-86. PubMed ID: 22416775 [TBL] [Abstract][Full Text] [Related]
18. Preclinical pharmacologic evaluation of pralatrexate and romidepsin confirms potent synergy of the combination in a murine model of human T-cell lymphoma. Jain S; Jirau-Serrano X; Zullo KM; Scotto L; Palermo CF; Sastra SA; Olive KP; Cremers S; Thomas T; Wei Y; Zhang Y; Bhagat G; Amengual JE; Deng C; Karan C; Realubit R; Bates SE; O'Connor OA Clin Cancer Res; 2015 May; 21(9):2096-106. PubMed ID: 25677697 [TBL] [Abstract][Full Text] [Related]
19. Emerging therapies in multiple myeloma. El-Amm J; Tabbara IA Am J Clin Oncol; 2015 Jun; 38(3):315-21. PubMed ID: 23934133 [TBL] [Abstract][Full Text] [Related]
20. T time: Emerging and new therapies for peripheral T-cell lymphoma. Mina A; Pro B Blood Rev; 2022 Mar; 52():100889. PubMed ID: 34716031 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]